Antibody

Regeneron said that a single dose of its antibody cocktail REGEN-COV reduced the risk for COVID-19 by nearly 82% up to 8 months after administration in a phase 3 trial.

A single dose of the novel antibody combination, REGN5713/14/15, appeared well-tolerated and demonstrated rapid and sustained inhibition of birch allergy symptoms, according to phase 1 study results.

The monoclonal antibody cocktail of bamlanivimab plus etesevimab reduced the risk for COVID-19-related death and hospitalization among high-risk ambulatory patients compared with placebo, according to phase 3 trial results published today.

Efgartigimod, a human IgG1 antibody designed to decrease pathogenic IgG autoantibody levels, demonstrated efficacy and tolerability among patients with generalized myasthenia gravis, according to findings published in The Lancet Neurology.

Regeneron’s antibody cocktail reduced the risk for death by 20% in patients hospitalized with severe COVID-19 who had not mounted their own immune response, researchers from the phase 3 RECOVERY trial said Wednesday.

Adults with obesity or severe obesity who test positive for COVID-19 are more likely to have peak antibody titer levels compared with those without obesity, according to a study published in Obesity.

One subcutaneous injection of REGEN-COV — a combination of two monoclonal antibodies — reduced the risk for symptomatic SARS-CoV-2 infection by more than 80% among household contacts of infected individuals, Regeneron said.

Clinicians developed a model for distributing COVID-19 neutralizing monoclonal antibody treatments that they said may be useful for other large health systems.

Results from a phase 1 first-in-human study evaluating NGM621, an anti-complement C3 antibody, in geographic atrophy secondary to age-related macular degeneration showed the therapy was safe and well tolerated.

Researchers demonstrated for the first time that infusions of antibodies can prevent HIV infection.